Posted by Michael Wonder on 19 Jul 2023
Severe asthma treatment Cinqair passes drug review 6 years after approval
7 July 2023 - Teva Handok's severe asthma treatment Cinqair (reslizumab) crossed the threshold of the Drug Benefit Evaluation Committee (DBEC) Thursday, six years after it won approval from the Ministry of Food and Drug Safety.
The seventh DBEC meeting this year also recognised the appropriateness of reimbursement for Roche Korea’s Vabysmo (faricimab), the first bispecific antibody treatment for ophthalmic diseases, and Eisai Korea’s Jyseleca (filgotinib), the oral Janus Kinase (JAK) inhibitor, if they accept amounts below assessment.
